AKT1 and diffuse large B-cell lymphoma: We and others have previously shown that downregulation of PTEN, a major negative regulator of the PI3K/AKT signaling is significantly associated with chemotherapy resistance and poor survival in patients with DLBCL with AKT hyperactivation [17–19].